Page 78 - 51 the significance--29.2_opt

80. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic,
and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology
2011;141(1):150-6.
81. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, et al. Effects of
glucagon-like peptide 1 on counterregulatory hormone responses, cognitive func-
tions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp
experiments in healthy volunteers. The Journal of clinical endocrinology and metabo-
lism 2002;87(3):1239-46.
82. Ahren B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, et al. Vildagliptin
enhances islet responsiveness to both hyper- and hypoglycemia in patients with
type 2 diabetes. The Journal of clinical endocrinology and metabolism 2009;94(4):
1236-43.
83. Merck Sharpe & Dohme Ltd. Januvia® US Prescribing Information. 2010.
84. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
JAMA 2002;287(3):360-72.
85. Novartis Europharm Ltd. Galvus® Prescribing Information. 2010.
86. Bristol-Myers Squibb Pharmaceuticals Ltd and AstraZeneca EEIG. Onglyza® Pre-
scribing Information. 2010.
87. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al.
Statement by an American Association of Clinical Endocrinologists/American
College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm
for glycemic control. Endocr Pract 2009;15(6):540-59.
88. ADA. Standards of medical care in diabetes--2009. Diabetes care 2009;32 Suppl 1:
S13-61.
89. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical
management of hyperglycemia in type 2 diabetes: a consensus algorithm for the
initiation and adjustment of therapy: a consensus statement of the American
Diabetes Association and the European Association for the Study of Diabetes.
Diabetes care 2009;32(1):193-203.
90. Sibal L, P.D. H. Management of type 2 diabetes: NICE guidelines. Clin Med 2009;9(4):
353-57.
91. International Diabetes Federation, Clinical guidelines taskforce. Global guideline for
type 2 diabetes. Brussels: International Diabetes Federation, 2005.
92. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes
care 2003;26(10):2929-40.
93. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide,
a long-acting glucagon-like peptide-1 analog, reduces body weight and food
intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vilda-
gliptin, does not. Diabetes 2007;56(1):8-15.
94. Eli-Lilly. Byetta 5 micrograms solution for injection SPC. 2009.
95. NovoNordisk. Victoza 6 mg/ml solution for injection in pre-filled pen. 2009.
96. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide
(exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with
type 2 diabetes. Diabetes care 2004;27(11):2628-35.
97. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide
(exendin-4) on glycemic control and weight over 30 weeks in metformin-treated
patients with type 2 diabetes. Diabetes care 2005;28(5):1092-100.
98. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects
of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2
diabetes treated with metformin and a sulfonylurea. Diabetes care 2005;28(5):1083-91.
99. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide
versus sitagliptin for patients with type 2 diabetes who did not have adequate
glycaemic control with metformin: a 26-week, randomised, parallel-group, open-
label trial. Lancet;375(9724):1447-56.
100. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide
once a day versus exenatide twice a day for type 2 diabetes: a 26-week
randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;
374(9683):39-47.
101. Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose
homeostasis and diabetes. Trends Mol Med 2008;14(4):161-8.
102. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide
effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in
patients with type 2 diabetes treated for at least 3 years. Current medical research
and opinion 2008;24(1):275-86.

78